Quantcast

Renal Solutions Adds Two New Members to Medical Advisory Board

June 17, 2008

WARRENDALE, Pa., June 17 /PRNewswire/ — Renal Solutions, Inc (RSI), a wholly-owned subsidiary of Fresenius Medical Care, announced today the addition of two members to its Medical Advisory Board, Jose Diaz-Buxo, M.D., FACP and Todd Ing, M.D.

Dr. Diaz-Buxo is Chief Medical Officer and Senior Vice President, Renal Therapies Group, Fresenius Medical Care North America. He is also Senior Advisor for Global Home Therapies, Fresenius Medical Care. He is known for his development of continuous cyclic peritoneal dialysis and various PD cyclers, his development of external occlusion for PD disconnect systems, and early identification of acute renal failure from contrast material injection. Dr. Diaz-Buxo has been a physician at the Mayo Clinic, the Carolinas Medical Center, the University of North Carolina, Chapel Hill, and has served on multiple editorial and review boards, including Clinical Nephrology, Peritoneal Dialysis International, Kidney International, and American Journal of Kidney Diseases. He has published more than 270 peer-reviewed papers, editorials and book chapters. He has received awards from the American Kidney Fund, the National Kidney Foundation and been listed in the Best Doctors in America and Who’s Who in Medicine.

Dr. Ing has previously worked as a staff physician in the Department of Medicine at the Veterans Affairs Hospital in Hines, IL. He has provided renal care to veterans for more than 25 years and has organized educational seminars for patients and healthcare professionals alike. He has been on the editorial boards for the International Journal of Artificial Organs, Artificial Organs, Transactions of the American Society for Artificial Internal Organs, Kidney, Journal of American Paraplegia Society, Hemodialysis International and Peritoneal Dialysis International. Dr. Ing has authored more than 250 publications in the area of dialysis with emphasis on isolated ultrafiltration, complications of dialysis, dialysate composition and peritoneal dialysis. He is also co-editor of the Handbook of Dialysis which is widely used around the world. He was presented the National Torchbearer Award by the American Kidney Fund in 2005. The American Association of Kidney Patients (AAKP) recently presented the Medal of Excellence Award to Dr. Ing.

“We are delighted to have Dr. Diaz-Buxo and Dr. Ing join our Medical Advisory Board,” said Peter DeComo, President and CEO of Renal Solutions. “The addition of these distinguished, renal experts to our advisory board of well known and highly experienced physicians further demonstrates Renal Solutions’ and Fresenius’ commitment to advancing sorbent therapy for improved renal care.”

RSI is the leader in advancing sorbent technology for renal replacement therapy in acute or chronic dialysis settings. The company was acquired by Fresenius Medical Care in November of 2007.

About Renal Solutions, Inc

Renal Solutions, a wholly-owned subsidiary of Fresenius Medical Care, is leading the advancement of sorbent technology for improved renal replacement therapy. Renal Solutions’ patented, innovative sorbent cartridges require only 6 liters of potable tap water, the lowest volume option available, to provide highly pure dialysate for up to 8 hours of therapy. SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) provides freedom from complex water treatment systems, opening new treatment options across chronic and acute dialysis settings. Backed by over 6 million safe and effective clinical treatments, SMARRT is a proven technology that will ultimately drive renal replacement therapy toward true portability and future wearable technology.

For more information about Renal Solutions visit the Company’s website at http://www.renalsolutionsinc.com/.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company’s products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Renal Solutions, Inc

CONTACT: Media Inquiries, Jennifer Bannan, Zer0 to Five, LLC,+1-412-580-3675, jen@0to5.com; Commercial Inquiries, Sue Bentley, MarketingDirector, Renal Solutions, Inc, +1-724-772-6900 ext. 109,sue.bentley@renalsolutionsinc.com

Web site: http://www.renalsolutionsinc.com/




comments powered by Disqus